Condor Software Raises $24 Million to Bring AI‑Powered Financial Intelligence to Life Sciences

Condor’s platform is designed to automatically unify disparate datasets — including clinical trial data, operational metrics and accounting records — into a consolidated, AI‑driven view that enables life sciences teams to see, predict and control the cost of bringing therapies to patients. By embedding proprietary clinical and financial ontologies into its workflows, the software aims to reduce manual data reconciliation, provide audit‑grade visibility and accelerate decision‑making for teams managing large, complex programs.

The company’s CEO, Jennifer Kyle, originally built many of the accounting workflows that pharmaceutical organizations use today, and she founded Condor to address specific pain points around data fragmentation that often slow project execution and inflate costs in clinical development. By applying machine intelligence to unify and interpret data automatically, Condor’s platform seeks to help sponsors and CROs operate with greater confidence and efficiency during long‑running trials.

Investors backing the round highlighted the increasing demand for software solutions that address both operational and financial complexity in life sciences, where the costs of drug development and regulatory compliance continue to rise. As pharmaceutical companies adopt more digital tools and automation, platforms that integrate cross‑functional data and provide predictive insights are gaining traction as strategic assets in managing risk and improving outcomes.

Analysts say the funding reflects broader industry shifts toward cloud‑native platforms, AI‑driven analytics and software‑centric workflows in drug development, clinical operations and financial planning, replacing legacy systems that often operate in silos. With the new capital, Condor plans to expand its engineering and go‑to‑market teams, enhance platform capabilities and deepen integrations with existing enterprise systems used by pharma sponsors and service partners.

The announcement adds to a wave of investment in life sciences software this year, where the convergence of AI, data management and regulatory compliance has created a fertile market for tools that help pharmaceutical organizations optimize complex processes from discovery through commercialization.